Lifileucel: the first cellular therapy approved for solid tumours.

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI:10.1016/j.trecan.2024.04.003

Max Julve, Mark P Lythgoe, James Larkin, Andrew J S Furness

引用次数: 0

Abstract

The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.

查看原文本刊更多论文

Lifileucel：首个获准用于实体瘤的细胞疗法。

美国食品和药物管理局（FDA）批准使用lifileucel治疗晚期黑色素瘤，这是首个用于实体瘤临床治疗的细胞疗法。在此，我们总结了这一具有里程碑意义的批准，考虑了相关的监管途径，并评估了为确保有效实施这种先进的 "活 "疗法所面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.